Indian Generics Look To Benefit From Obama Administration
This article was originally published in PharmAsia News
Executive Summary
Indian pharmaceutical makers expect to benefit from the change in administrations in the United States, with a new emphasis on support for generic drugs. India pharma insiders believe the Barack Obama administration will reform the health care system to make drugs more affordable and accessible, according to one analyst. That emphasis is seen as increasing generics use. India has more than 100 generics plants already approved by the U.S. FDA, he said, but noted the financial crisis would continue pressure to keep expenses down. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.